SUMMARY This paper compares the efficacy of tolmetin, prednisolone, and placebo (vehicle only) in controlling post-cataract extraction inflammation in a double-blind trial involving 120 patients. Seventeen patients were excluded from analysis. The results of the 103 patients analysed showed that 94% of the prednisolone treated group was judged to have been successfully treated as compared with 53% of the tolmetin treated group and 46% of the vehicle treated group. The differences between the prednisolone treated group and the other two groups were statistically significant (p<0.001). No statistical significance was found between the tolmetin and vehicle groups.
(NSAID) which acts by inhibiting prostaglandin synthesis.' Animal studies have shown tolmetin to reduce the level of inflammation in anterior uveitis.2
These studies have also shown that tolmetin did not tend to raise intraocular pressure as can be the case with prolonged use of topical steroids.3
The use of topical steroids following cataract surgery is common practice, and it is not unusual for this treatment to be continued for several weeks, which can lead to a rise in intraocular pressure.45 An agent controlling postoperative inflammation without this effect would be a useful addition to the clinician's armoury. This has led to a double-blind controlled clinical trial to compare the efficacy of tolmetin 2%, prednisolone 0*5%, and placebo (tolmetin vehicle) in the inflammation following uncomplicated intracapsular cataract extraction.
Material and methods
One hundred and twenty patients for intracapsular cataract extraction without intraocular lens implantation were selected for study. The following criteria excluded patients from the trial: (1) current treatment with systemic antiinflammatory agents; (2) glaucoma, uveitis, or corneal disease; (3) operative use of a-chymotrypsin; (4) age under 60.
The study was randomised, doule-blind, and conducted at two centres concurrently. Randomisation 
Results
Of the 120 patients entered into the trial 17 were excluded from analysis for various reasons (Table 2) .
Of the 103 patients analysed, 34 received tolmetin, 35 received vehicle, and 34 received prednisolone. The results are summarised in Table 3 . Apart from a statistically significantly lower proportion of males to females in the vehicle group, compared with the other two treatment groups, no major imbalance in age, race and side treated between treatment groups was detected (Table 4) . Eighteen out of 34 (53%) of the tolmetin treated group and 16 out of 35 (46%) of the vehicle treated group were considered to have been successfully treated as compared with 32 out of 34 (94%) patients in the prednisolone treated group. The differences between the prednisolone group and the other groups were highly significant (p<0001, X2 test), but no significant difference between the tolmetin group and the vehicle group was demonstrated.
Sixteen out of 34 (47%) of the tolmetin group, 19 out of 34 (54%) in the vehicle group, and two out of 34 (6%) of the prednisolone treated group were judged to be treatment failures. From the total symptom scores tolmetin (85%) and prednisolone (97%) appeared to relieve the symptoms of inflammation similarly and significantly better than vehicle (63%).
Although six out of 34 (18%) of the tolmetin group, three out of 35 (9%) of the vehicle group, and seven out of 34 (24%) of the prednisolone group had intraocular pressures over 22 mmHg during the trial, these differences were not found to be statistically significant. Seven out of 34 (21%) patients in the tolmetin group and four out of 35 (11%) in the vehicle, group reported discomfort, with the drops ranging from smarting and stinging to one case of severe burning sensation. No discomfort was reported in the prednisolone group.
Discussion
The results of this study indicated that prednisolone was the most effective treatment in reducing the clinical signs of inflammation and patient symptoms. It was also the best tolerated treatment.
There was no statistically significant difference between tolmetin and its vehicle in the resolution of postoperative inflammation. This suggested that the inflammation which follows surgical trauma can be self-limiting. However, tolmetin was significantly more effective than its vehicle in relieving symptoms. It could be inferred from this that tolmetin has an anti-inflammatory effect which is limited to the external ocular structures. This would cast doubt on the ocular penetrance of the drug in man, despite Double-blind controlled trial to compare anti-inflammatory effects oftolmetin, prednisolone, andplacebo 763 
